Sector
Health Tech & Life SciencesDigital HealthcareMedical Decision Support
Target Customer
Healthcare & Life SciencesLife SciencesBiotechnologyPharmaceuticalsHealthcareLaboratoriesProviders
Core Technology
Platforms & InterfacesSearch Engine
Tags (7)
biomarkersdigital-healthcaredrug-developmentclinical-trialsdisease-managementdrug-discoverydecision-support
Pheno.AI Financials
Undisclosed
Capital raised
Cumulative Funding Raised Over Time ($)
Pheno.AI Lifecycle
Cumulative Funding Raised Over Time
Pheno.AI News
1 article
Nvidia, Weizmann Inst., Pheno.ai develop glucose monitoring model
Pheno.AI, in collaboration with the Weizmann Institute of Science and NVIDIA, has developed GluFormer, an AI model designed to predict future glucose levels and other health metrics based on past data. This model, trained on data from over 10,000 non-diabetic participants, can forecast glucose responses to various actions and predict health outcomes like fatty tissue levels, blood pressure, and sleep apnea. The initiative, part of the Human Phenotype Project, aims to enhance human health through data analysis. The research is led by prominent figures from the Weizmann Institute and NVIDIA. This development is expected to aid pharmaceutical companies in predicting clinical trial outcomes and tailoring treatment plans for patients.
Partners
Pheno.AI Team
Ori Cohen
Co-founder & CEO
Founder
Boaz Shlevin
Chief Product Officer
Daniel Sass
Business Development Manager
Assaf Almog
Product Manager
Employee Info
| Employees (range) | 11-50 |
| Exact count | 44 |
| Team members | 4 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 12 classification IDs that could be used for matching.